Selective killing of gastric cancer cells by a small molecule targeting ROS-mediated ER stress activation

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Gastric cancer is a leading cause of cancer mortality worldwide.
• Curcumin, a natural product, has anticancer potential but limited clinical use due to poor stability.
• Novel, stable curcumin derivatives have been developed with enhanced anticancer properties.

Purpose of the Study:

• To investigate the anti-cancer effects and mechanisms of WZ26, a curcumin analog, in gastric cancer cells.
• To evaluate WZ26's efficacy in preclinical gastric cancer models.
• To elucidate the role of reactive oxygen species (ROS) in WZ26-induced apoptosis.

Main Methods:

• In vitro studies using gastric cancer cell lines (SGC-7901).
• Assessment of chemical stability, anti-proliferative effects, cell cycle arrest, and apoptosis induction.
• Mechanistic studies involving ROS production, JNK and ER stress pathway activation.
• In vivo evaluation using human gastric cancer cell xenograft models.

Main Results:

• WZ26 demonstrated superior chemical stability and anti-proliferative activity compared to curcumin.
• WZ26 induced dose-dependent cell cycle arrest and apoptosis in gastric cancer cells.
• WZ26 triggered ROS production, leading to JNK and ER stress pathway activation and apoptosis.
• Inhibition of ROS production abrogated WZ26-induced apoptosis and pathway activation.
• WZ26 exhibited significant anti-tumor effects in gastric cancer xenograft models.

Conclusions:

• WZ26 is a potent chemotherapeutic agent candidate for advanced gastric cancer treatment.
• Targeting ROS production to activate mitochondrial and ER stress pathways is a viable strategy for inducing tumor cell apoptosis.
• WZ26's enhanced stability and efficacy make it a promising therapeutic lead.